BTIG Rates Ascentage Pharma Group Internat (AAPG) buy

BTIG maintains a positive outlook on Ascentage Pharma Group with a reiterated buy rating and a $48 price target, a 180.37% upside from the current price.

By TradeTexts Research Desk · Published Jun 16, 2026, 6:00 AM EDT · Updated Jun 22, 2026, 12:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated Ascentage Pharma Group Internat ($AAPG) "buy" with a $48 price target on June 16, 2026.

Since the rating, $AAPG is up 0.0% after 1 week, up 19.9% after 1 month and down 9.6% to date (from the $17.01 close on Jun 16, 2026).

AAPG Ascentage Pharma Group Internat

$15.37 -41.71% year to date

Daily close · Oct 16, 2026

Key Points

BTIG reiterated its buy rating on Ascentage Pharma Group with a price target of $48 on June 16, 2026.
BTIG's $48 price target implies 180.37% upside from Ascentage Pharma Group Internat's ($AAPG) current $17.12 share price.
Ascentage Pharma Group, trading at $17.34, has a market cap of $1.62 billion and a 52-week range from $16.92 to $48.45.
Analysts are optimistic about AAPG, with a consensus strong buy rating and a target mean price of $47.56.

Get $AAPG trade alerts by text

We text you when insiders, Congress or big funds trade $AAPG. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Ascentage Pharma Group Internat alert may contain errors. Disclosures

On June 16, 2026, BTIG reiterated its buy rating on Ascentage Pharma Group Internat (NasdaqGM: AAPG), setting a price target of $48. This affirmation comes as the stock is trading at $17.34.

Analysts Set New Price Targets

BTIG's analyst Jeet Mukherjee reaffirmed the buy rating for Ascentage Pharma with a $48 target. On June 10, 2026, B. Riley Securities initiated coverage with a buy rating and a $45 target. Earlier in the year, on March 12, BTIG also assumed coverage with a buy rating and a similar $48 target. The consensus among analysts is a strong buy, with a target mean price of $47.56 based on nine opinions.

Ascentage Pharma Group Internat Stock Up 14.0%

Shares of Ascentage Pharma Group Internat are currently trading at $17.34. The company, with a market cap of approximately $1.62 billion, operates in the biotechnology sector. It has a forward P/E ratio of -14.51, indicating it is not currently profitable. The stock's 52-week range spans from $16.92 to $48.45, with a 50-day moving average of $21.81 and a 200-day moving average of $28.21. Ascentage Pharma has a current ratio of 1.79 and a quick ratio of 1.69, with a debt-to-equity ratio of 148.38.

12-month forecast

$AAPG price target

Ascentage Pharma Group Internat daily closes and this analyst's $48 target. Not advice.

About Ascentage Pharma Group Internat

Ascentage Pharma Group International is a biotechnology company based in Suzhou, China. It focuses on developing therapies for cancer, chronic hepatitis B, and age-related diseases. The company's key products include HQP1351 for targeting BCR-ABL1 mutants, APG-2575 for hematologic malignancies, and APG-115 for solid tumors and hematological malignancies. Ascentage Pharma collaborates with various biotechnology and pharmaceutical companies to advance its research and development efforts.

Bottom Line

BTIG's reaffirmation of a buy rating and a $48 target price underscores continued confidence in Ascentage Pharma Group's potential. Ascentage Pharma remains a focal point for investors interested in the biotechnology sector, with analysts maintaining a strong buy consensus. While 13F filings offer a historical snapshot, the analyst ratings provide a forward-looking perspective on the company's prospects.